Clinical trial
Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With…
NCT00080782 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00080782 |
|---|---|
| Title | Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases |
| Official title | A Randomized Phase II Trial of Bone-Targeted Therapy Consisting of Strontium-89 and Doxorubicin With or Without Celecoxib in Androgen-Independent Prostate Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Cancer, Prostate Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Celecoxib, Doxorubicin Hydrochloride, Strontium chloride Sr 89 |
| Enrollment | 14 |
| Start date | Feb 1, 2002 |
| Primary completion | Apr 1, 2004 |
| Completion | Jan 1, 2005 |
| First posted | Apr 8, 2004 |
| Last update posted | Oct 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: